Speciality Medicines Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Speciality Medicines Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $345.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Speciality Medicines Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $345.1K Trade | TransData Nexus

Speciality Medicines Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $345.1K Total Trade · DGFT Verified

Speciality Medicines Limited is an Indian pharmaceutical exporter with a total trade value of $345.1K across 6 products in 2 therapeutic categories. Based on 76 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Pembrolizumab ($159.1K), Olaparib ($76.4K), Ustekinumab ($46.8K).

Speciality Medicines Limited — Export Portfolio & Destination Treemap

Speciality Medicines Limited pharmaceutical export portfolio — 6 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Speciality Medicines Limited? — Company Overview & Market Position

Speciality Medicines Limited, established on February 5, 2021, is a public limited company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U85300GJ2021PLC120022. As of March 31, 2023, Speciality Medicines Limited reported an annual revenue of approximately $2.8 million USD and a net profit of $264,620 USD. The company employs a dedicated team of 17 professionals committed to delivering high-quality pharmaceutical products. Speciality Medicines Limited specializes in the marketing and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, focusing on complex and chronic medical conditions. The company's product portfolio spans therapeutic areas such as oncology, immunology, neurology, and rare diseases.

What Does Speciality Medicines Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Pembrolizumab$159.1K 2Olaparib

Product Portfolio — Top 6 by Export Value

Speciality Medicines Limited exports 6 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Pembrolizumab	Advanced Oncology	$159.1K	20	8.2%	7
2	Olaparib	Advanced Oncology	$76.4K	15	8.3%	4
3	Ustekinumab	Biologics & Immunotherapy	$46.8K	11	3.7%	8
4	Lenvatinib	Advanced Oncology	$32.0K	14	1.5%	8
5	Nivolumab	Advanced Oncology	$28.6K	10	1.3%	5
6	Cabozantinib	Advanced Oncology	$2.2K	6	1.7%	13

Speciality Medicines Limited exports 6 pharmaceutical products across 2 therapeutic categories with a total export value of $345.1K. The top category is Advanced Oncology (86.5% of portfolio), followed by Biologics & Immunotherapy (13.5%), indicating a concentrated portfolio with the top 5 products accounting for 99.4% of total export value.

Speciality Medicines Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Speciality Medicines Limited operates modern, temperature-controlled warehouses in multiple locations, including India and Africa, to ensure the safe storage and distribution of its pharmaceutical products. While specific details about manufacturing plant locations and capacities are not publicly disclosed, the company's infrastructure supports its extensive distribution network across more than 20 states in India and over 35 countries globally.

3Key Leadership

The leadership team at Speciality Medicines Limited comprises individuals with extensive experience in the pharmaceutical industry. Parthkumar Babulal Goyani serves as the Managing Director, overseeing the company's strategic direction and operations. Sumeet Babulal Goyani holds the position of Whole-Time Director, contributing to the company's growth and development. Chandresh Madhubhai Unagar is also a Director, playing a pivotal role in the company's management. Additionally, Kalpesh Bharatbhai Pipaliya was appointed as the Chief Financial Officer (CFO) on August 29, 2025, bringing valuable financial expertise to the organization.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Speciality Medicines Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Speciality Medicines Limited has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has been actively involved in obtaining necessary regulatory approvals and market access in these regions. In March 2026, Speciality Medicines Limited announced its Initial Public Offering (IPO), aiming to raise ₹29.14 crore (approximately $3.5 million USD) by offering 2,350,000 equity shares at a price band of ₹117-124 per share. The proceeds from the IPO are intended to support the establishment of a dedicated Research and Development (R&D) center, product registrations in international markets, and marketing and promotional activities, indicating the company's commitment to enhancing its global footprint.

2Emerging Markets

Speciality Medicines Limited has strategically expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on these regions is facilitated by its adherence to international quality standards, such as Good Manufacturing Practice (GMP) certifications, which enhance its credibility and facilitate market entry. By leveraging these certifications, Speciality Medicines Limited aims to establish a robust presence in these emerging markets, catering to the growing demand for specialty pharmaceutical products.

Speciality Medicines Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Speciality Medicines Limited has been proactive in engaging with the U.S. Food and Drug Administration (FDA) to ensure compliance with regulatory standards. The company has registered its manufacturing facilities with the FDA, facilitating the export of its pharmaceutical products to the United States. While specific details regarding approved Abbreviated New Drug Applications (ANDAs) and Drug Master File (DMF) filings are not publicly disclosed, the company's adherence to international quality standards, such as GMP certifications, underscores its commitment to meeting FDA requirements. The company's proactive approach to regulatory compliance enhances its credibility and facilitates market access in the U.S.

2WHO & EU GMP

Speciality Medicines Limited has obtained Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU), demonstrating its commitment to maintaining high-quality manufacturing standards. These certifications are crucial for the company's operations, as they enable access to international markets and ensure that its products meet the stringent quality requirements of global health authorities. The company's adherence to WHO and EU GMP standards reflects its dedication to delivering safe and effective pharmaceutical products worldwide.

Speciality Medicines Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Speciality Medicines Limited operates in a competitive pharmaceutical export market, facing competition from both domestic and international companies. Key competitors include AmerisourceBergen, Entero Healthcare, Keimed, Sandor Medicaids, and Mahaveer Medi Sales. The company's focus on specialty pharmaceutical products, particularly in therapeutic areas such as oncology, immunology, neurology, and rare diseases, differentiates it from competitors. By offering a diverse portfolio of high-cost oral and injectable medications, Speciality Medicines Limited aims to capture a significant share of the market for complex and chronic medical conditions.

2Key Differentiators

Speciality Medicines Limited distinguishes itself through its commitment to quality, innovation, and customer-centric approach. The company's adherence to international quality standards, such as GMP certifications from WHO and the EU, ensures that its products meet stringent safety and efficacy criteria. Additionally, the company's focus on high-cost specialty pharmaceuticals for complex chronic conditions positions it as a provider of innovative solutions in therapeutic areas like oncology, immunology, neurology, and rare diseases. The establishment of a dedicated R&D center, as planned with the proceeds from the IPO, is expected to further enhance the company's capabilities in product development and innovation.

Strategic Position

Buyer Due Diligence Brief — Evaluating Speciality Medicines Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Speciality Medicines Limited has established a robust supply chain, sourcing pharmaceutical products from well-known Indian manufacturers. The company's adherence to Good Distribution Practice (GDP) certification ensures the safe and efficient distribution of its products. The company's export activities, as reported by TransData Nexus, include a total export value of $345,000 USD across 76 shipments, indicating a consistent and reliable export volume. The company's proactive approach to regulatory compliance and quality assurance further enhances its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure the quality and compliance of Speciality Medicines Limited's products:

FDA Registration: Confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Speciality Medicines Limited

How many pharmaceutical products does Speciality Medicines Limited export from India?

Speciality Medicines Limited exports 6 pharmaceutical products across 2 therapeutic categories. The top exports are Pembrolizumab ($159.1K), Olaparib ($76.4K), Ustekinumab ($46.8K), Lenvatinib ($32.0K), Nivolumab ($28.6K). Total export value is $345.1K.

What is Speciality Medicines Limited's total pharmaceutical export value?

Speciality Medicines Limited's total pharmaceutical export value is $345.1K, based on 76 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Speciality Medicines Limited cover?

Speciality Medicines Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (86.5%, 5 products), Biologics & Immunotherapy (13.5%, 1 products).

Get Full Speciality Medicines Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.